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Background: In head-to-head randomized trials, everolimus-eluting stents (EES; Xience V) have proven superior to paclitaxel-eluting stents (Taxus). 
However, a more appropriate comparator device is the sirolimus-eluting stent (SES; Cypher) due to its high antirestenotic efficacy and its similar 
limus-based elution strategy.
Methods: In the ISAR-TEST-4 trial, we randomized 1304 patients with coronary artery disease to receive either EES (n=652) or SES (n=652). 
Angiographic follow-up was scheduled at 6-8 months. The primary endpoint was a device-oriented composite of cardiac death, myocardial infarction 
(MI) related to the target vessel and target lesion revascularization (TLR) at 12 months.
Results: The primary endpoint occurred in 13.6% of EES patients vs. 15.2% of SES patients (RR 0.81 [95% CI, 0.60-1.10]; p=0.46; see figure). 
Definite stent thrombosis occurred at a rate of 0.6% with EES vs. 1.3% with SES (RR 0.50 [95% CI, 0.15-1.62]; p=0.25). There was a trend towards 
lower rates of TLR and binary angiographic restenosis (BAR) in favor of the EES (see figure). A similar trend was observed with late luminal loss (EES 
0.23±0.57mm vs. SES 0.28±0.52mm; p=0.08).
Conclusions: EES were associated with comparable clinical outcomes to SES at 12 months post implantation. A trend towards higher 
antirestenotic efficacy was observed with EES.
